Suppr超能文献

使用 OROS 甲基苯丙胺对 ADHD 青少年进行[Tc-] TRODAT-1 SPECT 遗传成像研究。

Genetic imaging study with [Tc-] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate.

机构信息

Deparment of Child and Adolescent Psychiatry, Dokuz Eylul University, Izmir, Turkey.

Deparment of Nuclear Medicine, Dokuz Eylul University, Izmir, Turkey.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:294-300. doi: 10.1016/j.pnpbp.2018.04.008. Epub 2018 Apr 20.

Abstract

AIM

To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-] TRODAT-1SPECT in a sample of treatment-naïve adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability.

METHODS

Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment.

RESULTS

Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 ± 33.77, post-treatment DAT binding: 208.86 ± 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 ± 55.24, post-treatment DAT binding: 285.66 ± 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability.

CONCLUSION

Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-] TRODAT-1SPECT.

摘要

目的

使用 [Tc-] TRODAT-1SPECT 检查未经治疗的青少年注意缺陷多动障碍(ADHD)患者接受两个月安非他命控释制剂(OROS-MPH)治疗对大脑的影响。此外,评估风险等位基因(多巴胺转运蛋白 1 基因的 10 重复等位基因纯合性)是否与纹状体多巴胺转运蛋白可用性的改变有关。

方法

20 名患有 ADHD 的青少年在开始 OROS-MPH 治疗并将剂量提高至 1mg/kg/天后,接受脑单光子发射计算机断层扫描(SPECT)[Tc-] TRODAT-1 扫描。在开始 OROS-MPH 治疗前、1 个月和 2 个月后,使用临床总体印象量表(CGI-S)和 DuPaul ADHD 评定量表-临床版(ARS)评估疾病严重程度。

结果

ADHD 青少年接受 OROS-MPH 治疗后,右侧尾状核(治疗前 DAT 结合率:224.76±33.77,治疗后 DAT 结合率:208.86±28.75,p=0.02)和右侧壳核(治疗前 DAT 结合率:314.41±55.24,治疗后 DAT 结合率:285.66±39.20,p=0.05)的多巴胺转运蛋白可用性降低。对 OROS-MPH 反应良好的 ADHD 青少年(n=7)右侧壳核的多巴胺转运蛋白密度下降幅度明显大于对 OROS-MPH 反应较差的青少年(n=13)(p=0.02)。然而,两组间的治疗反应差异与右侧尾状核的多巴胺转运蛋白密度无关。多巴胺转运蛋白 1 基因(DAT1 基因)中的风险等位基因(多巴胺转运蛋白 1 基因的 10 重复等位基因纯合性)与纹状体多巴胺转运蛋白可用性的改变无关。

结论

OROS-MPH 治疗两个月会降低右侧尾状核和壳核的多巴胺转运蛋白可用性。对 OROS-MPH 反应良好的 ADHD 青少年右侧壳核的多巴胺转运蛋白密度下降幅度更大。然而,我们的研究结果不支持 DAT1 基因的 10 重复等位基因纯合性与使用 [Tc-] TRODAT-1SPECT 评估的多巴胺转运蛋白密度之间存在关联。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验